{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Valido E"],"funding":["European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement","European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement","Swiss Paraplegic Foundation"],"pagination":["12825"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11997090"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Individuals with spinal cord injury/disease (SCI/D) have a high incidence of urinary tract infections (UTI). This randomized controlled pilot trial investigated the effect of an immunomodulator (Uro-Vaxom) versus a placebo on the urinary tract microbiome of individuals with SCI/D to inform the design of a larger trial. Twenty participants with SCI/D undergoing primary rehabilitation were randomized to receive either Uro-Vaxom or a placebo for three months (ClinicalTrials.gov NCT04049994 08/08/2019). Urine was collected at baseline, immediately post-treatment, and three months post-treatment. DNA was extracted and sequenced using full-length 16 S rRNA using Oxford Nanopore technology. Internal controls were added for absolute abundance estimation. There were 10 participants in Uro-Vaxom and"],"journal":["Scientific reports"],"pubmed_title":["Effects of Uro-Vaxom vs. placebo on the urinary tract microbiome in individuals with spinal cord injury in a randomized controlled pilot trial (Uro-Vaxom pilot)."],"pmcid":["PMC11997090"],"funding_grant_id":["801076"],"pubmed_authors":["Krebs J","Wollner J","Stoyanov J","Valido E","Bertolo A","Pannek J"],"additional_accession":[]},"is_claimable":false,"name":"Effects of Uro-Vaxom vs. placebo on the urinary tract microbiome in individuals with spinal cord injury in a randomized controlled pilot trial (Uro-Vaxom pilot).","description":"Individuals with spinal cord injury/disease (SCI/D) have a high incidence of urinary tract infections (UTI). This randomized controlled pilot trial investigated the effect of an immunomodulator (Uro-Vaxom) versus a placebo on the urinary tract microbiome of individuals with SCI/D to inform the design of a larger trial. Twenty participants with SCI/D undergoing primary rehabilitation were randomized to receive either Uro-Vaxom or a placebo for three months (ClinicalTrials.gov NCT04049994 08/08/2019). Urine was collected at baseline, immediately post-treatment, and three months post-treatment. DNA was extracted and sequenced using full-length 16 S rRNA using Oxford Nanopore technology. Internal controls were added for absolute abundance estimation. There were 10 participants in Uro-Vaxom and","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2026-06-03T01:12:12.872Z","creation":"2025-06-26T03:06:07.664Z"},"accession":"S-EPMC11997090","cross_references":{"pubmed":["40229352"],"doi":["10.1038/s41598-025-96939-y"]}}